Trial Profile
A Multi-Center, Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Corticosteroids
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 29 Jun 2012 Planned end date changed from 1 Apr 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 24 Jan 2011 Planned end date changed from 1 Dec 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 30 Oct 2009 Planned end date changed from 1 May 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.